Comparing the current results to its competitors, Springworks Therapeutics Inc reported Revenue increase in the 1 quarter 2025 by 133.68 % year on year. The sales growth was above Springworks Therapeutics Inc 's competitors' average revenue growth of 5.64 %, achieved in the same quarter.
Springworks Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 1329.24 %
Springworks Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates within the pharmaceutical industry, which is characterized by rapid technological change and intense competition. Its competitors include major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and both public and private research organizations. The company’s products, OGSIVEO and GOMEKLI, compete with approved treatments, off-label therapies, and potential future therapies. Key competitive factors include efficacy, safety, administration method, cost, promotional activities, and intellectual property protection. Several competitors possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. As of November 27, 2023, OGSIVEO is the first and only FDA-approved therapy for desmoid tumors. Named competitors include BioDiscovery, Inc. and Vivace Therapeutics, Inc. Additionally, smaller or early-stage oncology-focused therapeutics companies may pose competition, particularly through collaborations with larger firms. Competition also exists in recruiting personnel, establishing clinical trial sites, enrolling patients, and acquiring technology. The availability of reimbursement from government and private payors will affect product pricing and market competitiveness.
Due to outstanding performance in Overall company, revenue grew by 133.68 % Springworks Therapeutics Inc improved its market share, to approximately 0.07 %.
August 28, 2024
Recent advancements in the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) have centered around SpringWorks Therapeutics investigational MEK inhibitor, mirdametinib. This article provides an in-depth examination of the U.S. Food and Drug Administration (FDA) granting priority review to the New Drug Application (NDA) for mirdametinib, alongside the company s initiation of a rolling submission to the FDA. These significant milestones in the drug development process underscore the potential impact of mirdametinib on therapeutic approaches for both pediatric and adult patients afflicted with NF1-PN, a rare and debilitating genetic disorder.Neurofibromatosis type 1 (NF1) is a g...
July 1, 2024
SpringWorks Therapeutics Submits New Drug Application to FDA for Mirdametinib in Treatment of Neurofibromatosis Type 1-Plexiform NeurofibromasSTAMFORD, Conn., July 01, 2024 - SpringWorks Therapeutics, a leading biopharmaceutical company specializing in severe rare diseases and cancer, announced today the successful completion of the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for mirdametinib. This investigational MEK inhibitor has shown great promise in treating pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the growth of tumors, known as plex...
March 4, 2024
SpringWorks Therapeutics Initiates New Drug Application for Mirdametinib for the Treatment of Neurofibromatosis Type 1-Associated Plexiform NeurofibromasSpringWorks Therapeutics, a leading biopharmaceutical company, has announced the initiation of a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib. This investigational MEK inhibitor shows promising potential as a treatment for pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The initiation of the NDA filing marks a significant milestone in the quest to address the severe rare disease.Mirdametinib and NF1-PNNeurofibromatosis type 1 (NF1) is...
Publicly Traded Peers of Springworks Therapeutics Inc
Iovance Biotherapeutics inc Share Performance
+1.81%
Over The Past 5 Days
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Revolution Medicines Inc operates as a biopharmaceutical company that focuses on discovering and developing new drugs to target cancers and other diseases caused by defects in cellular signaling. Their business model involves leveraging their expertise in precision oncology and molecular biology to identify novel drug candidates and advance them through preclinical and clinical development stages.
Sources:
Springworks Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Springworks Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
